NEW YORK (GenomeWeb News) — DioGenix announced today that it raised $3.2 million in a private financing that will support an ongoing prospective clinical trial of its next generation sequencing-based multiple sclerosis test, MS Precise.

The financing involved both new and returning individual investors, the company said, including life sciences fund Nerveda, whose president, Cam Gallagher, is also chairman of DioGenix. Other investors were not named.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene regulation changes linked to human brain evolution, and more.

The New York Stem Cell Foundation's Initiative on Women in Science and Engineering working group presents seven strategies to promote gender equality in the sciences.

Researchers link a genetic variation to the ability to quickly process arsenic in people living in the Andes Mountains.

A small portion of pregnant women who've undergone non-invasive prenatal testing have found out from the test that they have cancer.